⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL65025 | 1.00 | GABRR1 (0.59) | — | |
| SCHEMBL352933 | 1.00 | — | — | |
| SCHEMBL352934 | 1.00 | — | — | |
| SCHEMBL373882 | 1.00 | — | — | |
| SCHEMBL3404693 | 1.00 | GABRR1 (0.59) | — | |
| SCHEMBL15444681 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL28929366 | 0.96 | GABRR1 (0.56) | — | |
| Hydrochloric Acid SCHEMBL28665294 | 0.96 | GABRR1 (0.56) | — | |
| Ammonia Solution, Strong SCHEMBL11489327 | 0.96 | GABRR1 (0.56) | — | |
| Hydrochloric Acid SCHEMBL20556849 | 0.96 | GABRR1 (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158350-A1 | ESTER ANALOGS OF PSILOCIN, PROCESSES FOR THE PREPARATION THEREOF, AND METHODS OF USE | INVYXIS, INC. | 2024-05-16 | — | — | US | claimed |
| WO-2024081961-A2 | ESTER ANALOGS OF PSILOCIN, PROCESSES FOR THE PREPARATION THEREOF, AND METHODS OF USE | INVYXIS, INC. (US) | 2024-04-18 | — | — | WO | claimed |
| US-20250214977-A1 | STAT6 INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-07-03 | — | — | US | disclosed |
| CN-112074513-B | Pyridine and pyrazine derivatives as preferential cannabinoid 2 agonists | 豪夫迈·罗氏有限公司 | 2024-06-14 | — | — | CN | disclosed |
| US-11999710-B2 | Radiolabeled cannabinoid receptor 2 ligand | HOFFMANN-LA ROCHE INC. (US) | 2024-06-04 | — | — | US | disclosed |
| US-20240158350-A1 | ESTER ANALOGS OF PSILOCIN, PROCESSES FOR THE PREPARATION THEREOF, AND METHODS OF USE | INVYXIS, INC. | 2024-05-16 | — | — | US | disclosed |
| WO-2024081961-A2 | ESTER ANALOGS OF PSILOCIN, PROCESSES FOR THE PREPARATION THEREOF, AND METHODS OF USE | INVYXIS, INC. (US) | 2024-04-18 | — | — | WO | disclosed |
| EP-4341386-A2 | METHODS FOR THE EXPANSION OF HUMAN GRANULOCYTEMACROPHAGE PROGENITORS AND APPLICATIONS THEREOF | University of Southern California (US) | 2024-03-27 | — | — | EP | disclosed |
| CN-116640118-A | Radiolabeled cannabinoid receptor 2 ligands | 豪夫迈·罗氏有限公司 | 2023-08-25 | — | — | CN | disclosed |
| US-11655243-B2 | Pyridine and pyrazine derivatives as preferential cannabinoid 2 agonists | HOFFMANN-LA ROCHE INC. (US) | 2023-05-23 | — | — | US | disclosed |
| CN-112638430-B | Radiolabeled cannabinoid receptor 2 ligands | 豪夫迈·罗氏有限公司 | 2023-05-16 | — | — | CN | disclosed |
| WO-2019069270-A1 | MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-04-11 | — | — | WO | disclosed |
| US-20180057528-A1 | INDOLINE COMPOUNDS AS GRANZYME B INHIBITORS | VIDA THERAPEUTICS INC. (CA) | 2018-03-01 | — | — | US | disclosed |
| US-9605021-B2 | Indoline compounds as granzyme B inhibitors | VIDA THERAPEUTICS INC. (CA) | 2017-03-28 | — | — | US | disclosed |
| US-20160083422-A1 | INDOLINE COMPOUNDS AS GRANZYME B INHIBITORS | VIDA THERAPEUTICS INC. (CA) | 2016-03-24 | — | — | US | disclosed |
| US-20140249105-A1 | NOVEL CERAMIDE ANALOGUES, PROCESSES FOR PREPARING SAME AND USES THEREOF | DIVERCHIM (FR) | 2014-09-04 | — | — | US | disclosed |
| US-20140249105-A1 | NOVEL CERAMIDE ANALOGUES, PROCESSES FOR PREPARING SAME AND USES THEREOF | DIVERCHIM (FR) | 2014-09-04 | — | — | US | disclosed |
| WO-2008112251-A1 | CYCLOPROPYL-CONTAINING POLYAMINE ANALOGS AS DISEASE THERAPIES | PROGEN PHARMACEUTICALS, INC. (US) | 2008-09-18 | — | — | WO | disclosed |
| EP-0771196-B1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 1999-12-08 | — | — | EP | disclosed |
| US-5717109-A | CARBOXYCYCLOPROPYL GLYCINE DERIVATIVES; USEFUL FOR TREATMENT OF ACUTE OR CHRONIC NEURODEGENERATIVE CONDITIONS, AND AS ANTIPSYCHOTIC, ANTICONVULSANT, ANALGESIC, ANXIOLYTIC, ANTIDEPRESSANT AND ANTI-EMETIC AGENTS | ELI LILLY AND COMPANY (US) | 1998-02-10 | — | — | US | disclosed |